News & Views
Latest News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets
Sign up for more news
Thank you